Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | REN | P00797 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920313 | 0.86 | REN (0.33) | RORCRENLMNA | |
| SCHEMBL2923663 | 0.85 | RORC (0.34) | RORCREN | |
| SCHEMBL4647994 | 0.84 | REN (0.32) | RORCREN | |
| SCHEMBL2917645 | 0.84 | REN (0.32) | RORCREN | |
| SCHEMBL2920668 | 0.84 | REN (0.35) | NPC1RORCMAPTREN | |
| SCHEMBL2919256 | 0.83 | RORC (0.34) | RORCMAPTREN | |
| Bromide SCHEMBL2685772 | 0.81 | REN (0.37) | MAPTREN | |
| Bromide SCHEMBL2920715 | 0.81 | LMNA (0.36) | NPC1MAPTLMNA | |
| SCHEMBL2925177 | 0.79 | RORC (0.33) | RORCREN | |
| SCHEMBL2917120 | 0.79 | RORC (0.33) | RORCREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863803-B1 | SUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1958634-A2 | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
| EP-1863803-A2 | SUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | NPC1 3393/4885RORC 4757/4885MAPT 3109/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | NPC1 1614/4885RORC 2727/4885MAPT 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.